Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation

Wan Du1,2, Fang Hua1,2, Xiong Li1,2, Jian Zhang1,2, Shasha Li1,2, Weichao Wang1,2, Jiajia Zhou1,2, Weimin Wang1,2, Peng Liao1,2, Yijian Yan1,2, Gaopeng Li1,2, Shuang Wei1,2, Sara Grove1,2, Linda Vatan1,2, Witold Zgodziński3, Marek Majewski3, Grzegorz Wallner3, Haoyan Chen4, Ilona Kryczek1,2, Jing-Yuan Fang4, and Weiping Zou1,2,5,6,7,8
ABSTRACT
Mutations in IFN and MHC signaling genes endow immunotherapy resistance. Patients with colorectal cancer infrequently exhibit IFN and MHC signaling gene mutations and are generally resistant to immunotherapy. In exploring the integrity of IFN and MHC signaling in colorectal cancer, we found that optineurin was a shared node between the two pathways and predicted colorectal cancer patient outcome. Loss of optineurin occurs in early-stage human colorectal cancer. Immunologically, optineurin deficiency was shown to attenuate IFNGR1 and MHC-I expression, impair T-cell immunity, and diminish immunotherapy efficacy in murine cancer models and patients with cancer. Mechanistically, we observed that IFNGR1 was S-palmitoylated on Cys122, and AP3D1 bound with and sorted palmitoylated IFNGR1 to lysosome for degradation. Unexpectedly, optineurin interacted with AP3D1 to prevent palmitoylated IFNGR1 lysosomal sorting and degradation, thereby maintaining IFNγ and MHC-I signaling integrity. Furthermore, pharmacologically targeting IFNGR1 palmitoylation stabilized IFNGR1, augmented tumor immunity, and sensitized checkpoint therapy. Thus, loss of optineurin drives immune evasion and intrinsic immunotherapy resistance in colorectal cancer.

SIGNIFICANCE: Loss of optineurin impairs the integrity of both IFNγ and MHC-I signaling pathways via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation, thereby driving immune evasion and intrinsic immunotherapy resistance in colorectal cancer. Our work suggests that pharmacologically targeting IFNGR1 palmitoylation can stabilize IFNGR1, enhance T-cell immunity, and sensitize checkpoint therapy in colorectal cancer.

See related commentary by Salvagno and Cubillos-Ruiz, p. 1623.

INTRODUCTION
Immune therapies induce durable responses across diverse cancers, including melanoma, lung cancer, and bladder cancer (1, 2). Colorectal cancer is one of the most frequently diagnosed and fatal cancers worldwide. Approximately 15% of patients with colorectal cancer exhibit high microsatellite instability (MSI) or deficient mismatch repair (3–5) and could be sensitive to immune checkpoint therapy (6, 7). Hence, the majority of patients with colorectal cancer do not respond to current immunotherapy. In order to explore and realize the full potential of immune checkpoint blockade in patients with colorectal cancer, it is essential to identify unknown intrinsic immune evasion and resistance mechanisms in these patients.

Multiple immunosuppressive mechanisms have been demonstrated in the cancer microenvironment (8). Recent compelling evidence has established a connection between genetic and epigenetic alterations and immunotherapy resistance. For example, genetic lesions in the IFN and antigen-presenting signaling pathways are a defined mechanism for cancer immune evasion and immunotherapy resistance. Mutations in B2M, JAK1, and JAK2, resulting in loss of MHC-I expression or poor response to IFNγ, are observed in patients with adaptive resistance to immunotherapy (9–11). Meanwhile, copy-number alterations in MHC-I and IFNγ signaling genes are also found in patients with intrinsic resistance to immunotherapy (9–12). Additionally, tumors may evade tumor immunity by impairing effector T-cell trafficking into the tumor microenvironment via altered β-catenin signaling (13), epigenetic mechanisms (14, 15), and other biological pathways (16–18). Although patients with colorectal cancer are generally not responsive to immunotherapy, genetic mutations in the IFN signaling pathway and antigen-presenting-machinery genes are infrequently observed in these patients. For example, B2M mutations are harbored in 3.4% patients with colorectal cancer (19), and JAK1 mutation is found in 5.3% of patients with microsatellite stable (MSS) colorectal cancer. Therefore, we questioned if there existed broad, yet unknown, immunologic mechanisms that may be fundamentally responsible for immune evasion and intrinsic immunotherapy resistance in patients with colorectal cancer. Given that resistance to the IFNγ and MHC-I signaling pathways is a major immune evasion mechanism (20), in this

1Department of Surgery, University of Michigan School of Medicine, Ann Arbor, Michigan. 2Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan School of Medicine, Ann Arbor, Michigan. 3The 2nd Department of General Surgery, Medical University of Lublin, Lublin, Poland. 4State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 5Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan. 6Graduate Program in Immunology, University of Michigan School of Medicine, Ann Arbor, Michigan. 7Graduate Program in Tumor Biology, University of Michigan School of Medicine, Ann Arbor, Michigan. 8University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, Michigan.

Note: Supplementary data for this article are available at Cancer Discovery Online (http://cancerdiscovery.aacrjournals.org/).

W. Du and F. Hua contributed equally to this article.

Corresponding Author: Weiping Zou, Department of Surgery, University of Michigan School of Medicine, 109 Zina Pitcher Place, Ann Arbor, MI 48109. Phone: 734-615-5554; E-mail: wzou@med.umich.edu

Cancer Discov 2021;11:1826–43
doi: 10.1158/2159-8290.CD-20-1571
©2021 American Association for Cancer Research
work we focus on the integrity of the IFNγ and MHC-I signaling pathways in patients with colorectal cancer. We found that loss of tumor optineurin expression altered IFNGR1 protein stability and affected the integrity of the IFN signaling and antigen-presenting machinery, as well as T cell–mediated antitumor immunity, thereby influencing immunotherapy sensitivity. Thus, loss of optineurin may be a previously unappreciated intrinsic immune evasion and checkpoint blockade resistance mechanism in patients with colorectal cancer.

RESULTS

Tumor Optineurin Correlates with Immunotherapy Efficacy and Patient Outcome

Patients with colorectal cancer infrequently exhibit IFN and MHC signaling gene mutations. To understand why these patients are generally resistant to immunotherapy, we examined IFN signaling and antigen-presenting gene expression in colorectal cancer and normal colorectal tissues. We initially compared both IFN and MHC-I gene signatures in colorectal cancers in The Cancer Genome Atlas (TCGA) dataset. After stringent filtering criteria, we selected the top 500 genes from each individual gene signature. Among the top 500 genes, 322 genes were shared between IFN and MHC-I signaling signatures in colorectal cancers (Fig. 1A). Among these 322 shared genes, we uncovered 15 highly expressed proteins in normal colorectal tissues according to the protein expression score of the Human Protein Atlas (www.proteinatlas.org/pathology; Fig. 1A). Then, we conducted a proteomic study in 96 paired colon cancer tissues and adjacent normal colon tissues (21). Among the aforementioned 15 proteins, we detected nine proteins (optineurin, DDX60, GIMAP1, IFI35, HLA-B, PARP14, SAMD9L, TAP1, and EPSTI1) in the paired colon cancer tissues and adjacent normal colon tissues. Interestingly, optineurin protein levels were decreased in colon cancer tissues as compared with levels in paired normal adjacent tissues, and optineurin was the most often reduced among these nine proteins, with reduction occurring in 83% of cases (Fig. 1A; Supplementary Table S1). These results were confirmed in an additional colorectal cancer tissue proteomic analysis (ref. 22; Fig. 1B). To directly validate these proteomic results, we assessed optineurin expression with immunohistochemistry staining in colorectal cancer tissues and paired adjacent normal tissues. The intensity of optineurin expression was lower in colorectal cancer tissues than paired adjacent normal tissues (Fig. 1C; Supplementary Fig. S1A).

Given that cancer tissues contain tumor cells and different immune cells, we assessed optineurin expression at single cell levels in the human colorectal cancer microenvironment. We first analyzed single-cell sequencing data in human colorectal cancer tissues (23). We found that optineurin transcripts were decreased in colorectal cancer epithelial cells as compared with adjacent normal colorectal epithelial cells (Supplementary Fig. S1B). Interestingly, optineurin mRNA levels in T cells, B cells, and macrophages were similar in colorectal cancer tissues when compared with adjacent normal colorectal tissues (Supplementary Fig. S1C–S1E). We next compared optineurin protein levels in paired fresh colorectal cancer tissues and adjacent normal colorectal tissues (Supplementary Fig. S1F–S1K). Flow cytometry analysis revealed that optineurin protein levels were lower in colorectal cancer epithelial cells when compared with adjacent normal colorectal epithelial cells (Supplementary Fig. S1G), whereas optineurin protein levels in CD8+ T cells, B cells, macrophages, and dendritic cells were not significantly different between the two groups (Supplementary Fig. S1H–S1K). We extended our studies from colorectal cancer to other types of cancer. Again, we showed reduced levels of optineurin transcripts in colorectal cancer, breast cancer, and lung cancer when compared with adjacent normal tissues in TCGA datasets (Supplementary Fig. S1L–S1N). We next explored the immunologic relevance of optineurin in colorectal cancer. Along this line, we found optineurin positively correlated with HLA-A, HLA-B, and HLA-C in colorectal cancer (Supplementary Fig. S2A). Similar results were obtained in breast cancer and lung cancer (Supplementary Fig. S2B and S2C). Altogether, these results suggest that optineurin is a potential immune-associated gene, and its expression is selectively lost in these human cancers.

To evaluate a potential kinetic alteration of optineurin expression in the course of colorectal cancer development, we included colorectal adenoma in our studies. Similar to colorectal cancer, we found optineurin expression was decreased in colorectal adenoma as compared with normal colorectal tissues (Fig. 1D). The data reveal an early loss of optineurin expression in the progression of colorectal carcinogenesis. Additionally, cancer optineurin expression negatively correlated with colorectal cancer histologic grades (Fig. 1E) and advanced TNM stages (Fig. 1F; Supplementary Fig. S2D and S2E). Furthermore, low expression of cancer optineurin was associated with poor prognosis in patients with colorectal cancer (Fig. 1G; Supplementary Fig. S2F; Supplementary Tables S2 and S3). Optineurin expression did not correlate with patient gender, age, or tumor localization (Supplementary Fig. S2G–S2I). These observations were validated in different colorectal cancer patient cohorts (Fig. 1C–G; Supplementary Fig. S2D–S2I; Supplementary Tables S2–S5).

Patients with melanoma, but not with colorectal cancer, are responsive to checkpoint immunotherapy. In order to explore the clinical significance of optineurin in cancer immunotherapy in patients with cancer, we examined the relationship between optineurin protein expression and immunotherapy efficacy in patients with melanoma (24). Interestingly, the proteomic analysis demonstrated that clinical benefit rates, including complete response and partial response (PR), were higher in patients with high levels of optineurin protein expression compared with those with low levels of optineurin protein (Fig. 1H). Moreover, high optineurin protein expression was positively associated with patient survival in patients with melanoma treated with anti-PD-1 therapy (Fig. 1I). Proteomic and genomic (22) analyses demonstrated that tumor optineurin protein expression failed to correlate with tumor MSI status in patients with colorectal cancer (Supplementary Fig. S2J). Patients with high MSI are sensitive to immunotherapy (7). The data suggest that loss of tumor optineurin expression may be a novel immune evasion mechanism and tumor optineurin is an independent factor determining clinical response to immunotherapy in patients with colorectal cancer. Collectively, loss of optineurin expression correlates with low immune gene signature
Figure 1. Tumor optineurin correlates with immunotherapy efficacy and patient outcome. A, Overlapping genes between the IFN and MHC-I signaling pathways in human colorectal cancer in the TCGA dataset. Left, based on log FC > 0 and P values, the top individual genes (500) and shared genes (322) were identified in the IFN signaling and MHC-I signatures in the TCGA dataset. Middle, among the shared 322 genes, based on protein expression score values, the top individual genes (500) and shared genes (322) pathways in human colorectal cancer in the TCGA dataset. Left, based on log FC P = 0.1741. E, Optineurin expression in different histologic grades of colorectal cancer (n = 92; cohort 1). Two-tailed t-tests; ***, P < 0.001. F, Optineurin protein expression detected by immunohistochemistry staining in normal colorectal tissues and paired adjacent normal colorectal tissues (cohort 1; n = 66). Optineurin expression was quantified by H-score method. Paired t-tests; ****, P < 0.0001. C, Optineurin protein expression detected by immunohistochemistry staining in normal colorectal tissues and paired adjacent normal colorectal tissues (cohort 1; n = 66). Optineurin expression was quantified by H-score method. Paired t-tests; ****, P < 0.0001. NS, not significant. P = 0.01. G, Survival was analyzed and compared between patients with low (n = 39) and high (n = 39) levels of optineurin in colorectal cancer. Log-rank test. H and I, Relationship between optineurin protein expression and immunotherapy efficacy in patients with melanoma. H, The clinical response rates to anti–PD-1 therapy in patients with melanoma with high and low optineurin expression are shown. The clinical beneficial group (CB) included complete response (CR; n = 10) and PR (n = 30); the no clinical beneficial group (NCB) included progressive disease (n = 27). χ² test; ***, P < 0.001. I, Survival was analyzed and compared between patients with low (n = 34) and high (n = 33) levels of optineurin in patients with melanoma treated with anti–PD-1 therapy. Log-rank test.
Optineurin affects tumor immunity and immunotherapy efficacy. 
A and B, Effect of optineurin knocking down on murine colorectal tumor growth. Tumor growth was monitored in syngeneic wild-type mice bearing scramble and sh-optineurin-expressing MC38 cells (A) and CT26 cells (B). Mean ± SEM, n = 8 or 9 per group (A) and n = 10 per group (B); ***P < 0.0001 on day 30 (A) and day 22 (B, two-way ANOVA) C–E, Effect of optineurin KO (optineurin−/−) on MC38 tumor growth. Tumor growth was monitored in C57BL/6 wild-type mice bearing optineurin−/− and optineurin−/− MC38 cells. Tumor volume (C), weight (D), and images (E) are shown. Mean ± SEM, n = 10 per group. ****P < 0.0001 on day 30 (two-way ANOVA). Scale bars, 1 cm (E).

F and G, Effect of IEC-optineurin KO on murine colorectal tumorigenesis in AOM/DSS model. Tumor numbers, size (F), and images (G) are shown, n = 6 per group. Two-tailed t-test; ***, P < 0.001. Scale bars, 2 mm (G).

H, Effect of optineurin KO on immunotherapy efficacy in MC38 tumor-bearing mice. Mice bearing optineurin−/− and optineurin−/− MC38 tumors were treated with anti–PD-L1 mAb. *, P < 0.05; **, P < 0.01; ***, P < 0.001 on day 16 (two-way ANOVA).

Optineurin Affects Tumor Immunity and Immunotherapy Efficacy

Our results suggest that optineurin may play a role in tumor immunity. To test this possibility, we genetically knocked down optineurin with specific short hairpin RNAs (shRNA; sh-optineurin-1 and sh-optineurin-2) in murine MC38 colon cancer cells (Supplementary Fig. S3A). MC38 cells expressing sh-optineurin and scramble control similarly proliferated in vitro (Supplementary Fig. S3B). We inoculated these cells into NOD-scidIL2Rγcnull (NSG; immune-deficient) mice and wild-type (immune-competent) syngeneic C57BL/6 mice. We observed comparable tumor growth curve, tumor volume, and tumor weight in NSG mice bearing sh-optineurin and scramble MC38 tumors (Supplementary Fig. S3C–S3E). In contrast, sh-optineurin-expressing, MC38 tumor-bearing C57BL/6 mice exhibited faster tumor growth compared with control mice (Fig. 2A). We additionally knocked down optineurin in murine CT26 colon cancer cells (Supplementary Fig. S3F) and inoculated these cells into wild-type (immune-competent) syngeneic BALB/c mice. Again, knocking down tumor optineurin resulted in faster CT26 tumor progression (Fig. 2B). To confirm, we constructed optineurin knockout (KO) MC38 colon cancer cells (optineurin−/−; Supplementary Fig. S3G) using optineurin-specific CRISPR/Cas9 KO plasmid and inoculated these cells into C57BL/6 mice.

Similarly, optineurin genetic KO resulted in faster MC38 tumor growth, larger tumor volume, and increased tumor weight compared with control (Fig. 2C–E).

To further solidify these data in a colitis-associated colorectal cancer model, we crossed floxed optineurin (optineurinF/F) mice with Villin-cre mice and generated intestinal epithelial cell (IEC)-specific optineurin-deficient (optineurinΔIEC) mice. We isolated IECs and confirmed specific intestinal epithelial optineurin deletion (Supplementary Fig. S3H). We challenged these mice with azoxymethane (AOM) and dextran sulfate sodium salt (DSS) to induce colorectal tumor development. We found an increase in intestinal tumor numbers and sizes in optineurinΔIEC (optineurin−/−) mice as compared with optineurinF/F (optineurin+/+) mice (Fig. 2F and G), whereas the intestinal length was comparable in optineurin+/+ and optineurin−/− mice (Supplementary Fig. S3I). These data indicate that tumor optineurin affects antitumor immunity during colorectal tumor development. Differing from Rag1−/− mice, innate immune cells may be quantitatively and qualitatively impaired in NSG mice due to IL2 signaling deficiency. To explore whether innate immunity or adaptive immunity was predominantly affected by tumor optineurin expression, we inoculated MC38 colon cancer cells into Rag1−/− mice. Similar to the NSG mice, tumor optineurin deficiency did not alter tumor growth, weight, and volume in Rag1−/− mice (Supplementary Fig. S3J–S3L). This result suggests that tumor optineurin affects adaptive immunity in colorectal cancer in vivo.
MC38 tumor model is sensitive to PD-L1 and PD-1 blockade (25, 26). To test whether tumor optineurin altered MC38 sensitivity to immunotherapy, we treated mice bearing optineurin+/+ and optineurin+/− MC38 tumors with anti–PD-L1 monoclonal antibody (mAb). We found that mice bearing optineurin+/+ MC38 tumors were less sensitive to anti–PD-L1 mAb therapy as compared with those bearing optineurin+/− MC38 tumors (Fig. 2H). Thus, loss of tumor optineurin drives immune evasion and reduces immunotherapy efficacy.

**Optineurin Affects Cytotoxic T-cell Activation and Function In Vivo**

To explore the immune mechanism by which loss of tumor optineurin may drive immune evasion, we analyzed immune cell subsets in the tumor microenvironment in mice bearing optineurin genetic knockdown tumors (Fig. 3A–C; Supplementary Fig. S4A–S4I) and KO tumors (Fig. 3D–F; Supplementary Fig. S4J and S4K). We detected comparable amounts of tumor-infiltrating CD8+ T cells in mice bearing sh-optineurin and scramble CT26 tumors (Supplementary Fig. S4B). However, the levels of granzyme B, TNFα, and IFNγ in tumor-infiltrating CD8+ T cells (Fig. 3A–C) and CD4+ T cells (Supplementary Fig. S4C–S4E) were reduced in sh-optineurin CT26 tumors, whereas PD-1+CD8+ T cells and TIM3+CD8+ T cells were comparable (Supplementary Fig. S4F and S4G).

The levels of IL2 and FOXP3 in CD4+ T cells were comparable (Supplementary Fig. S4F and S4G). In vivo depletion of T cells in mice bearing sh-optineurin−/− and optineurinΔIEC (optineurin−/−) mice with melanoma treated with immunotherapy (24). Tumor activation, and effector T-cell signaling proteins in patients with melanoma (Fig. 3J; Supplementary Fig. S5A–S5C). In accordance with the data from in vivo results, the level of H-2Kb protein was also decreased in the IECs in optineurin+/− mice compared with that in optineurin+/+ mice in the AOM/DSS model (Fig. 4C).

To assess whether optineurin deficiency restricted CD8+ T-cell cytotoxic activities due to impaired MHC-I expression, we cultured mouse ovalbumin (OVA)-specific CD8+ T cells (OT-I) with OVA-expressing optineurin−/− and optineurin+/− MC38 tumor cells. Tumor optineurin deficiency resulted in a decrease in CD8+ T-cell cytotoxic activities, as shown by reduced 7-AAD+ optineurin−/− MC38 tumor cells when compared with optineurin+/− MC38 tumor cells (Fig. 4D). These data correspond with a reduced SIINFEKL-(OVA-peptide)–H-2Kb complex expression in optineurin−/− MC38 tumor cells as compared with optineurin+/− MC38 tumor cells (Fig. 4E).

We then explored how MHC-I expression was reduced in optineurin-deficient tumor cells. Given that MHC-I is often regulated by IFNγ pathway, we assessed the potential relationship between optineurin and the IFNγ pathway. We stimulated tumor cells with IFNγ and observed reduced expression of IFNGR1 protein and STAT1 phosphorylation in sh-optineurin LS174T tumor cells (Supplementary Fig. SSD) and optineurin−/− LS174T tumor cells (Supplementary Fig. SSE and SSF) compared with control cells, indicating that optineurin alters IFNGR1 expression and STAT1 activation. To test if this effect is specific to the IFNγ and STAT1 signaling pathway, we included PD-L1, a well-known IFNγ responsive gene, STAT3, and STAT5 in our experiments. We found that IFNγ-induced PD-L1 expression and STAT5 phosphorylation (Supplementary Fig. SSF) and IL6-induced STAT3 phosphorylation (Supplementary Fig. SSG) were slightly reduced in optineurin−/− LS174T tumor cells when compared with wild-type LS174T tumor cells.

These results suggest a predominant regulatory role of optineurin on the IFNGR and STAT1 pathway. We inoculated and established optineurin−/− MC38, sh-optineurin CT26, and control tumors into syngeneic wild-type mice. Consistent with the in vitro data, immunohistochemistry staining detected a decrease in IFNGR1 expression in optineurin−/− MC38

**Optineurin Deficiency Impairs IFNGR1 Expression and Antigen Presentation**

We next examined how optineurin deficiency prevents CD8+ T-cell activation. High tumor optineurin expression correlated with MHC-I expression in human colorectal cancer (Fig. 1A; Supplementary Fig. S2A) and T-cell activation signaling in patients with melanoma (Fig. 3J; Supplementary Fig. S4L). CD8+ T-cell activation is mediated by the engagement of T-cell receptor to the antigen-derived peptide–MHC-I complex. In line with this, we detected a decrease in the H2-Kb transcripts (Fig. 4A) and mean fluorescence intensity (MFI) of H-2Kb protein (Fig. 4B) in optineurin−/− MC38 tumor cells as compared with optineurin+/− MC38 tumor cells. This difference persisted in the presence of IFNγ stimulation (Fig. 4A and B). The levels of HLAABC transcripts were also reduced in optineurin knockdown human colon cancer LS174T cells (Supplementary Fig. S5A–S5C). In accordance with the in vivo results, the level of H-2Kb protein was also decreased in the IECs in optineurin−/− mice compared with that in optineurin+/+ mice in the AOM/DSS model (Fig. 4C).

To assess whether optineurin deficiency restricted CD8+ T-cell cytotoxic activities due to impaired MHC-I expression, we cultured mouse ovalbumin (OVA)-specific CD8+ T cells (OT-I) with OVA-expressing optineurin−/− and optineurin+/− MC38 tumor cells. Tumor optineurin deficiency resulted in a decrease in CD8+ T-cell cytotoxic activities, as shown by reduced 7-AAD+ optineurin−/− MC38 tumor cells when compared with optineurin+/− MC38 tumor cells (Fig. 4D). These data correspond with a reduced SIINFEKL-(OVA-peptide)–H-2Kb complex expression in optineurin−/− MC38 tumor cells as compared with optineurin+/− MC38 tumor cells (Fig. 4E).

We then explored how MHC-I expression was reduced in optineurin-deficient tumor cells. Given that MHC-I is often regulated by IFNγ pathway, we assessed the potential relationship between optineurin and the IFNγ pathway. We stimulated tumor cells with IFNγ and observed reduced expression of IFNGR1 protein and STAT1 phosphorylation in sh-optineurin LS174T tumor cells (Supplementary Fig. SSD) and optineurin−/− LS174T tumor cells (Supplementary Fig. SSE and SSF) compared with control cells, indicating that optineurin alters IFNGR1 expression and STAT1 activation. To test if this effect is specific to the IFNγ and STAT1 signaling pathway, we included PD-L1, a well-known IFNγ responsive gene, STAT3, and STAT5 in our experiments. We found that IFNγ-induced PD-L1 expression and STAT5 phosphorylation (Supplementary Fig. SSF) and IL6-induced STAT3 phosphorylation (Supplementary Fig. SSG) were slightly reduced in optineurin−/− LS174T tumor cells when compared with wild-type LS174T tumor cells.

These results suggest a predominant regulatory role of optineurin on the IFNGR and STAT1 pathway. We inoculated and established optineurin−/− MC38, sh-optineurin CT26, and control tumors into syngeneic wild-type mice. Consistent with the in vitro data, immunohistochemistry staining detected a decrease in IFNGR1 expression in optineurin−/− MC38
Figure 3. Optineurin affects cytotoxic T-cell activation and function in vivo. A–C, Effect of tumor optineurin knocking down on CT26 tumor infiltrating T cell function. Sh-optineurin and scrambled shRNA-expressing CT26 cells were inoculated into BALB/c mice. The percentages of tumor-infiltrating granzyme B+ (A), TNFα+ (B), and IFNγ+ (C) CD8+ T cells were analyzed by flow cytometry. Mean ± SEM, n = 9 per group. Two-tailed t-tests; ****, P < 0.001; ***, P < 0.0001. D–F, Effect of tumor optineurin deficiency on MC38 tumor-infiltrating T-cell function. Optineurin+/− and optineurin−/−-expressing MC38 cells were inoculated into C57BL/6 mice. The percentages of tumor-infiltrating granzyme B+ (D), TNFα+ (E), and IFNγ+ (F) CD8+ T cells were analyzed by flow cytometry. Mean ± SEM, n = 4 or 5 per group. Two-tailed t-tests; *, P < 0.05; **, P < 0.01. G–I, Effect of IEC-optineurin deficiency on T-cell function in the AOM/DSS model. The percentages of granzyme B+ (G), TNFα+ (H), and IFNγ+ (I) CD8+ T cells in LPMCs were analyzed by flow cytometry, n = 3 per group. Two-tailed t-tests; *, P < 0.05; **, P < 0.01. J, Correlation of optineurin protein expression with effector T-cell signaling signature in melanoma patients treated with anti-PD-1 therapy (n = 67).
Optineurin Controls Colorectal Cancer Immunity

Expression was quantified by flow cytometry on OVA-expressing MC38 cells. Optineurin deficiency impairs IFNGR1 expression, thereby attenuating tumor cell apoptosis as compared with optineurin+/+ MC38 cells. Optineurin or optineurin−/− MC38 cells were cocultured with OT-I tumor cells for 24 hours. Tumor cell apoptosis was determined by flow cytometry analysis. Results are shown as the percentages of 7-AAD+ tumor cells (%). Two-tailed t-tests; *, P < 0.01; **, P < 0.001; *** , P < 0.0001. (continued on next page)

In support of these mouse data, proteomics analysis in human melanoma (24) revealed that optineurin protein expression positively correlated with MHC-I complex and IFNγ signaling proteins (Fig. 4J). T-cell receptor signaling was attenuated in patients with low tumor optineurin expression (ref. 24; Supplementary Fig. S5L). Furthermore, we performed immunohistochemistry staining for IFNGR1 and optineurin in patients with colorectal cancer. We detected a positive correlation between IFNGR1 and optineurin in human colorectal cancer tissues (Fig. 4K; Supplementary Fig. S5M). Additionally, the levels of tumor IFNGR1 negatively correlated with colorectal cancer TNM stages (Fig. 4L) and were positively associated with patient survival (Fig. 4M). Thus, loss of optineurin reduces IFNGR1 expression, thereby impairing MHC antigen presentation and T-cell activation and driving immune escape in cancer.

**Loss of Optineurin Promotes IFNGR1 Lysosomal Sorting via AP3D1**

We explored the molecular mechanism by which optineurin controls IFNGR1 expression. We detected comparable levels of Ifngr1 mRNA in optineurin+/+ and optineurin−/− LS174T cells (Supplementary Fig. S6A) and mouse MC38 cells (Supplementary Fig. S6B). These results suggest that optineurin deficiency impairs IFNGR1 expression, thereby affecting the IFNγ signaling pathway. To further support this possibility, we transfected MC38 tumor cells with a GAS (IFNγ-activated site) reporter construct and measured Stat1 transcriptional activity. Optineurin deficiency caused a decrease in Stat1 transcriptional activity compared with control cells in response to IFNγ (Supplementary Fig. S5J). To determine the biological role of optineurin in IFNGR1 on CD8+ T-cell cytotoxicity, we generated Ifngr1−/− MC38 cells. Similar to optineurin−/− MC38 cells (Fig. 4E), Ifngr1−/− MC38 cells manifested a decrease in SIINFEKL-H-2Kb expression (Fig. 4F) and were resistant to OT-I cell-mediated killing (Fig. 4G). Then, we ectopically expressed Ifngr1 in wild-type and optineurin−/− MC38 cells. We rescued SIINFEKL-H-2Kb expression in optineurin−/− tumor cells and recovered their sensitivity to the CD8+ T-cell killing function (Fig. 4I).
optineurin−/− LS174T cells (Supplementary Fig. S6C). The data further suggest that optineurin deficiency promotes IFNGR1 protein degradation in lysosomes. We conducted an immunofluorescence staining for IFNGR1 and LAMP1, a lysosome marker, in optineurin−/− LS174T cells. As expected, loss of optineurin resulted in increased IFNGR1 localization in lysosomes, as shown by the co-staining of IFNGR1 and LAMP1 (Fig. 5C). The data provide evidence that optineurin deficiency promotes IFNGR1 degradation in lysosomes.

Optineurin is involved in basic cellular functions by interacting with several proteins (29). We postulated that optineurin directly interacts with IFNGR1 and regulates its stability. However, immunoprecipitation (IP) experiments failed to detect a direct interaction between optineurin and IFNGR1 in LS174T cells (Supplementary Fig. S6E). To identify potential binding partners of IFNGR1 and optineurin, we performed immunoprecipitation coupled with mass spectrometry (IP-MS) experiments. Interestingly, we detected that AP3D1 was the most abundant subunit in both IFNGR1 immunoprecipitates (Supplementary Fig. S6F) and optineurin immunoprecipitates (Supplementary Fig. S6G). Thus, AP3D1 is a potent binding partner of IFNGR1 and optineurin (Supplementary Fig. S6B). The data suggest that optineurin may regulate IFNGR1 protein stability rather than transcripts. To test this possibility, we evaluated the half-life of IFNGR1 in optineurin+/+ and optineurin−/− human colon cancer LS174T cells by blocking de novo IFNGR1 protein synthesis with cycloheximide (CHX). We found the half-life of IFNGR1 to be 24 hours. Tumor cell apoptosis was determined by flow cytometry analysis. Results are expressed as percentages of 7-AAD+ tumor cells. n = 3 biological replicates. Mean ± SEM; two-tailed t-tests; ***P < 0.001. J, Correlation of optineurin protein expression with the MHC complex and IFN signaling genes. Heat map shows MHC complex proteins and IFN signaling proteins in patients with melanoma treated with anti–PD-1 therapy (n = 67). Each color represents differential gene expression: red represents high expression; blue represents low expression. K, Correlation of optineurin and IFNGR1 protein expression in colorectal cancer tissues. Pearson correlation analysis. Expression of optineurin and IFNGR1 was determined by immunohistochemistry and expressed as H-score. Cohort 3, n = 78. L and M, Pathologic and clinical impact of tumor IFNGR1 protein on patients with colorectal cancer. IFNGR1 protein was examined by immunohistochemistry staining. L, IFNGR1 expression in different stages of patients with colorectal cancer. Cohort 3, n = 78. Two-tailed t-tests; ***, P < 0.0001. M, Survival was analyzed and compared between patients with low (n = 39) and high (n = 39) levels of IFNGR1 in colorectal cancer. Log-rank test. Cohort 3, n = 78.

![Image](https://example.com/image1.png)
Optineurin Controls Colorectal Cancer Immunity

**Figure 5.** Loss of optineurin promotes IFNGR1 lysosomal sorting via AP3D1. A−C, Role of optineurin in IFNGR1 degradation. A, Optineurin+/− and optineurin−/− LS174T cells were treated with CHX. Immunoblots revealed IFNGR1 expression bands (left) and relative band intensities (right) at different time points. One of three replicates is shown. B, Optineurin+/− and optineurin−/− LS174T cells were treated with bafilomycin for 4 hours. Immunoblots showed IFNGR1 expression. One of three replicates is shown. C, Effect of optineurin on tumor IFNGR1 lysosomal localization. Optineurin+/− and optineurin−/− DLD1 cells were stained for IFNGR1 (red) and LAMP1 (green). Cell nucleus (blue) was stained with 4′-6-diamidino-2-phenylindole (DAPI). Representative immunofluorescence images exhibit the colocalization of IFNGR1 and LAMP1. Scale bars, 5 μm; n = 3 biological replicates. D, Effect of AP3D1 on IFNGR1 expression. IFNGR1 expression in sh-AP3D1- and scrambled shRNA-expressing optineurin+/− and optineurin−/− LS174T cells. Immunoblots showed IFNGR1 expression; n = 3 biological replicates. (continued on next page)

Table S6). AP3D1 is one of the subunits of AP3, which is crucial for selection and trafficking of cargo into lysosomes (30–32). We hypothesized that AP3D1 was involved in IFNGR1 lysosomal sorting for degradation. To test this hypothesis, we knocked down AP3D1 with specific shRNAs in LS174T cells. As expected, knocking down AP3D1 resulted in an increase in IFNGR1 protein levels (Supplementary Fig. S6H) and a full rescue of IFNGR1 expression in optineurin−/− LS174T cells (Fig. S5D) and optineurin−/− DLD1 cells (Supplementary Fig. S6I). Moreover, knockdown of AP3D1 abolished the lysosomal localization of IFNGR1 in optineurin−/− DLD1 cells (Fig. S5E). These results suggest that loss of optineurin accelerates IFNGR1 lysosomal sorting via AP3D1 and subsequent lysosomal degradation.

Given that AP3D1 is a binding partner for both optineurin and IFNGR1, we wondered whether optineurin expression affected the binding of AP3D1 with IFNGR1. IP experiments with anti-AP3D1 and anti-IFNGR1 mAbs revealed higher levels of the IFNGR1–AP3D1 interaction in optineurin+/− LS174T cells and optineurin−/− DLD1 cells than in their optineurin+/− counterparts (Fig. S5F and G; Supplementary Fig. S6J). Consistent with these results, Duolink (IFNGR1–AP3D1) assay showed higher levels of the IFNGR1–AP3D1 interaction in optineurin−/− DLD1 cells (Fig. S5H). Collectively, the data suggest that loss of optineurin facilitates IFNGR1 binding with AP3D1 and heightens AP3D1-mediated IFNGR1 lysosomal sorting and degradation.

**IFNGR1 Palmitoylation Alters AP3D1–IFNGR1 Interaction and Tumor Immunity**

We dissected the mechanism by which loss of optineurin enhances AP3D1–IFNGR1 interaction, thereby accelerating IFNGR1 lysosomal sorting and degradation. Lipid modification, including palmitoylation, can regulate the protein–protein interaction (33–36). Some proteins require palmitoylation for adaptor protein recognition and lysosomal sorting (32, 37). This prompted us to consider whether IFNGR1 is palmitoylated and if IFNGR1 palmitoylation facilitates its interaction with AP3D1 for lysosomal sorting and degradation. To test this, we first treated LS174T cells with 2-bromopalmitate (2-BP), a palmitoylation inhibitor (Supplementary Fig. S7A), or palmostatin B, a depalmitoylation inhibitor (Supplementary Fig. S7B). We found that 2-BP increased and palmostatin B decreased IFNGR1 protein expression in a time-dependent manner (Supplementary Fig. S7A and S7B). Treatment with 2-BP fully rescued IFNGR1 expression in optineurin−/− LS174T cells (Fig. 6A). However, neither optineurin deficiency nor 2-BP treatment had an effect on expression of IL6 receptor (IL6R) and TNFR1 (Fig. 6A). However, neither optineurin deficiency nor 2-BP treatment had an effect on expression of IL6 receptor (IL6R) and TNFR1 (Fig. 6A). Click-iT assay detected potent IFNGR1 palmitoylation in optineurin−/− LS174T cells (Fig. 6B). We also detected IFNGR1 palmitoylation in vivo in optineurin−/− tumor cells isolated from the AOM/DSS-induced murine colon cancer model (Supplementary Fig. S7C). These data
reveal that IFNGR1 expression can be regulated through a previously unknown lipid modification (palmitoylation).

To determine whether IFNGR1 palmitoylation is critical for its interaction with AP3D1 in optineurin−/− cells, we treated optineurin−/− LS174T cells with 2-BP. Co-immunoprecipitation experiments showed that treatment with 2-BP reduced the interaction between IFNGR1 and AP3D1 and increased IFNGR1 expression in optineurin−/− LS174T cells (Fig. 6C). Duolink assay demonstrated that inhibition of palmitoylation with 2-BP attenuated the binding of IFNGR1 to AP3D1 in optineurin−/− DLD1 cells (Fig. 6D). These results suggest that the interaction between IFNGR1 and AP3D1 is dependent on IFNGR1 palmitoylation. To further validate this possibility, we employed the motif-based predictor MDD-Palm (38) and identified Cys122 as a single conservative palmitoylation site at IFNGR1 (Supplementary Fig. S7D) across species (Supplementary Fig. S7E). We substituted the Cys122 residue with alanine (C122A) and made a IFNGR1 C122A mutant through site-directed mutagenesis. This substitution abolished IFNGR1 palmitoylation (Fig. 6E) in optineurin−/− LS174T cells and reduced AP3D1–IFNGR1 interaction (Fig. 6F and G) in 293T cells (Fig. 6F) and optineurin−/− DLD1 cells (Fig. 6G). Therefore, IFNGR1 palmitoylation is required for its interaction with AP3D1.

Palmitoylation can police protein stability (39) and regulate protein lysosomal sorting (32, 37). As IFNGR1 degradation occurred in lysosome (Fig. 5), we next explored a connection between IFNGR1 palmitoylation and degradation in the context of optineurin. Indeed, treatment with palmostatin B enhanced the lysosomal localization of IFNGR1 (Supplementary Fig. S7F), whereas treatment with 2-BP reduced IFNGR1 in lysosomes in optineurin−/− DLD1 cells and enabled comparable levels of lysosomal-free IFNGR1 in optineurin−/− and optineurin C122A cells (Supplementary Fig. S7G). The data suggest that IFNGR1 palmitoylation accelerates its lysosomal sorting and degradation. For further confirmation, we treated LS174T cells with palmostatin B to promote IFNGR1 palmitoylation and examined a role of lysosome inhibitor in IFNGR1 degradation. As expected, palmostatin B promoted IFNGR1 degradation, and bafilomycin prevented palmitoylation-associated IFNGR1 degradation (Fig. 6H). CHX chase assay demonstrated that inhibition of palmitoylation delayed IFNGR1 degradation in optineurin−/− LS174T cells (Supplementary Fig. S7H). Moreover, the IFNGR1 C122A mutant enhanced IFNGR1 protein stability as compared with scramble control in optineurin−/− LS174T cells (Fig. 6I), resembling the effect of 2-BP (Supplementary Fig. S7H).
Furthermore, abrogation of palmitoylation with C122A mutation resulted in a decrease in lysosomal IFNGR1 and an increase in lysosomal-free IFNGR1 (Fig. 6J). Thus, IFNGR1 palmitoylation is essential for its interaction with AP3D1, and loss of optineurin results in an accelerated AP3D1-mediated IFNGR1 lysosomal sorting and degradation.

As IFNGR1 palmitoylation is essential for its interaction with AP3D1 and subsequent IFNGR1 lysosomal sorting and degradation, we explored whether suppression of IFNGR1 palmitoylation could restore cancer IFNGR1 expression and sensitize immunotherapy efficacy in a preclinical animal model. To this end, we aimed at identifying pharmacologic agents that could inhibit both mouse and human protein palmitoylation. Cerulenin, a natural product isolated from the fungi Cephalosporium caerulescens, was capable of inhibiting both mouse and human protein palmitoylation, as shown in RAW264.7 cells and 293T cells (40, 41). We treated human and mouse colon cancer cells with cerulenin in vitro. Cerulenin inhibited IFNGR1 expression in optineurin−/− CT26 cells (Supplementary Fig. S8A and S8B) and rescued IFNGR1 protein expression in optineurin−/− LS174T cells (Supplementary Fig. S8C), sh-optineurin CT26 cells (Supplementary Fig. S8D), and optineurin−/− primary intestinal epithelial tumor cells isolated from the AOM/DSS-induced murine tumor model (Supplementary Fig. S8E).

These results prompted us to evaluate a potential antitumor effect of cerulenin in a cancer immunotherapy setting in a preclinical murine model. We treated sh-optineurin CT26 tumor-bearing mice with cerulenin in combination with anti–PD-L1 mAb (Fig. 6K). As expected, treatment with anti–PD-L1...
alone had minimal effect on tumor growth, whereas cerulenin treatment alone partially inhibited tumor growth; however, the combination therapy manifested a synergistic antitumor effect, as shown by tumor volume (Fig. 6K) and weight (Fig. 6L) compared with control (Supplementary Fig. S8F). We detected higher levels of tumor H-2-Dd in mice treated with cerulenin, as compared with controls (Supplementary Fig. S8G). Moreover, the combination treatment resulted in high tumor-infiltrating CD8+ T-cell effector function as assessed by granzyme B and TNFα expression (Supplementary Fig. S8H and S8I). The data suggest that pharmacologic inhibition of IFNGR1 palmitoylation may be used in combination with checkpoint blockade to treat patients with poor immunogenic cancers, such as colorectal cancer. Because tumor-infiltrating antigen-presenting cells (APC) and T cells expressed optineurin (Supplementary Fig. S1), we evaluated a potential direct effect of cerulenin on T cells and APCs. We cultured T cells and bone marrow–derived macrophages with cerulenin in vitro. We found that treatment with cerulenin had no direct effect on T-cell activation, as shown by comparable levels of granzyme B, TNFα, and IFNγ expression in CD8+ T cells (Supplementary Fig. S8J–S8L). However, cerulenin enhanced expression of MHC-I (H-2Kβ) in mouse bone marrow–derived macrophages (Supplementary Fig. S8M). Thus, treatment with cerulenin may also target APCs in vivo.

**Discussion**

The remarkable clinical successes of immune checkpoint blockade therapies do not provide therapeutic benefit to the majority of patients with colorectal cancer (1, 2). Effector T cell–mediated cytotoxicity induces tumor cell death via apoptosis and ferroptosis (42, 43). However, tumor associated–antigen–specific T-cell priming and activation can be diminished due to tumor genetic alterations in the IFN signaling and/or antigen-presenting signaling pathways (44–47). Notably, genetic mutations in the IFN- and antigen-presenting pathways infrequently occur in patients with colorectal cancer. We reason that the expressionional and functional integrity of the IFN signaling and antigen-presenting gene pathways may ultimately shape cancer immunity and
immunotherapy efficacy in patients with colorectal cancer. In line with this concept, our bioinformatics, genetic, proteomic, functional, and model studies have revealed that optineurin transcripts and proteins are consistently reduced in cancer epithelial cells, but not in immune cells, in the colorectal cancer microenvironment. Furthermore, we have detected a gradual loss of optineurin from normal human colorectal tissues to adenoma and colorectal cancer. Although how loss of tumor optineurin occurs in the colorectal cancer microenvironment remains to be defined, it appears that optineurin expression is also reduced in other types of cancer, including breast cancer and lung cancer. Thus, loss of tumor optineurin may be a previously unknown broad immune evasion and checkpoint blockade resistance mechanism in patients with cancer.

Optineurin is defined as an autophagy receptor (48), yet its expression, regulation, and function in the context of immunity, including tumor immunity, are unknown. Genomic, bioinformatic, and proteomic analysis has uncovered optineurin shared in the IFNγ and MHC-I signaling pathways, and optineurin protein deficiency emerges in the majority of colon cancer tissues when compared with paired adjacent normal colon tissues. In line with our human data, we have demonstrated that loss of tumor optineurin drives tumor resistance to T cell–mediated tumor killing and results in tumor resistance to treatment with anti–PD-L1 blocking antibodies in the AOM/DSS-induced colon cancer model with specific optineurin deficiency in IECs and in several colon tumor cell–bearing syngeneic murine models. Given that patients with colorectal cancer are largely not treated with immunotherapy, we have extended our observations to patients with melanoma having received checkpoint therapy (24). We have found that high levels of optineurin protein correlate with increased clinical response to checkpoint therapy in these patients and are associated with improved patient survival (24). In addition, simultaneous analysis of human colon cancer proteogenomic profile has failed to reveal a correlation of optineurin protein expression with MSI status (22). Patients with high microsatellite instability can be treated with checkpoint therapy due to their high levels of frameshift mutations, leading to potential generation of immunogenic neoantigens (7). Thus, our data suggest that optineurin expression is different from MSI and could be an immunogenic mechanism and an independent risk factor for determining clinical response to immunotherapy in patients with colorectal cancer. Accordingly, our work not only demonstrates a novel immunologic function of optineurin but also generates compelling evidence that optineurin is a core gene controlling tumor immunity evasion and intrinsic resistance to immunotherapy.

IFNGR1 is essential for the transduction of IFNγ signaling (49). Unexpectedly, IFNGR1, but not IL6R and TNFR1, is rapidly degraded in optineurin-deficient colorectal cancer cells. Furthermore, we have demonstrated that IFNGR1 is S-palmitoylated at Cys122, and palmitoylated IFNGR1 is sorted by adaptor protein AP3D1 to lysosomes for degradation. The palmitoylated cysteine in IFNGR1 acts as a signal for AP3D1 recognition and interaction. Consequently, if IFNGR1 harbors such a lysosome sorting signal, there may exist a protective mechanism for IFNGR1 stability to ensure the integrity of the IFNγ signaling pathway in the human body. Indeed, optineurin functions as an executor to fulfill a protective duty for IFNγ signaling integrity. In line with this notion, we have found optineurin binds to AP3D1 and functions as a blocker to prevent AP3D1-directed lysosomal sorting and degradation of palmitoylated IFNGR1 (Supplementary Fig. S9). Mechanistically, this palmitoylation-dependent ménage à trois (optineurin–AP3D1–IFNGR1) molecular cascade may serve as a potential model for exploring the biological activities of numerous S-palmitoylation events but has not been previously reported. In the context of colorectal cancer, early loss of optineurin occurs in patients with adenoma and colorectal cancer, resulting in accelerated IFNGR1 degradation and impaired IFNγ and MHC-I signaling pathways. Given that AP3D1 recognizes and sorts palmitoylated IFNGR1 to lysosomes for degradation, we sought to target IFNGR1 palmitoylation for colorectal cancer therapy. Supporting this possibility, pharmacologic inhibition of palmitoylation can restore IFNGR1 and MHC expression, enhance tumor immunity, and sensitize checkpoint therapy in preclinical models. Our data suggest that this tumor immunity restoration primarily depends on induced IFNGR1 and MHC-I expression on tumor cells. Nonetheless, it remains possible that administration of a palmitoylation inhibitor, such as cerulenin, may target not only tumor cells but also other cells, including APCs.

In summary, our work identifies optineurin as a central molecular node, dually controlling the integrity of the IFNγ and MHC-I signaling pathways. Loss of optineurin is a previously unappreciated immune evasion and intrinsic resistance mechanism in colorectal cancer. Additionally, we provide proof of principle that targeting IFNGR1 stability, including palmitoylation, may overcome intrinsic immunotherapy resistance in patients with colorectal cancer.

METHODS

Reagents

Baflomycin (B1793), CHX (C8559), MG132 (474790), 2-BP (238422), palmitostatin B (50-873-8001), and SIINFEKL peptide (OVA 257-264; S7951) were obtained from Sigma-Aldrich. Cerulein (10085647) was obtained from Cayman Chemicals. Monensin solution (00–4505–51) was obtained from Thermo Fisher Scientific, and 2-mercaptoethanol (21985023) was obtained from Gibco. Recombinant human IFNγ (285-IF), human IL6 (206-IL), and mouse IFNγ (485-MI) were obtained from R&D Systems.

Plasmids

Plasmids expressing shRNAs targeting human optineurin (TRCN0000083746 and TRCN0000430429), mouse optineurin (TRCN0000178154 and TRCN0000182388), and human AP3D1 (TRCN00000298616 and TRCN0000293891) were obtained from Sigma-Aldrich. Double nickase plasmid (h) (sc-401851-NIC), optineurin double nickase plasmid (m) (sc-427990), and control double nickase plasmid (sc-437281) were obtained from Santa Cruz Biotechnology. Mouse Ifngr1 knockout plasmid was constructed as previously reported (43). Human IFNGR1 (Myc-DDK tagged; RC202761), mouse Ifngr1 (Myc-DDK tagged; MR226594), human AP3D1 (TurboGFP tagged; RG219366), and pCMV6-Entry Tagged Cloning Vector (PSI00001) were obtained from OriGene Technologies.

The IFNGR1 C122A mutant plasmid was generated based on human IFNGR1 (Myc-DDK tagged; RC202761, OriGene) by site-directed
mutagenesis using the Agilent QuickChange II Site-Directed Mutagenesis Kit (200523). Specific primers are included in Extended Data Table 7. Plasmids were purified by the QIAGEN QIAprep Spin Miniprep Kit (27106). Plasmids were sequenced to confirm the mutations.

**Cell Culture**

Human cells (including LS174T, DLD1, and 293T cells) and murine CT26 cells were purchased from the ATCC. Murine MC38 cells were obtained as previously reported (25). All cells were cultured at 37°C in a humidified atmosphere containing 5% CO2. Human LS174T cells were cultured in Eagle’s Minimum Essential Medium (EMEM; 30-2003, ATCC). Human DLD1 cells and murine CT26 cells were cultured in RPMI 1640 medium (SH3025501, HyClone). Human 293T cells and murine MC38 cells were cultured in DMEM (11995065, Gibco). All cell lines were supplemented with 10% FBS (FR61, Alkali Scientific Incorporated) and regularly tested for Mycoplasma contamination using the Lonza MycoAlert Mycoplasma Detection Kit (LT07-318) every 2 weeks. The latest date of the cells tested for Mycoplasma contamination was December 20, 2020. Cells were thawed at early passage and cultured for up to 12 weeks in total. Splenocytes were obtained from C57BL/6 mice and stimulated with anti-CD3 (2 μg/mL), anti-CD28 (1 μg/mL), IL2 (10 ng/mL), and 2-mercaptoethanol (50 μM) for 3 days. Bone marrow-derived macrophages were obtained from bone marrow after stimulation with granulocyte-macrophage colony-stimulating factor. Plasmids were purified by the QIAGEN QIAprep Spin Miniprep Kit (200523). Specific primers are included in Extended Data Table 7.

**Genetic Knockdown and KO Cells**

Plasmids expressing shRNA targeting optineurin or scramble sequences were packed into a lentivirus packaging construct and transduced into HEK293T cells with Lipofectamine 2000 transfection reagent (11668019, Invitrogen). LS174T, MC38, and CT26 cells were infected with shRNA expressing lentiviruses and selected with 2, 3, and 10 μg/mL puromycin (A1133803, Gibco). Colon cancer cells were transduced with optineurin double nickase plasmid (h) (sc-401851-NIC, Santa Cruz Biotechnology), optineurin double nickase plasmid (m) (sc-427990, Santa Cruz Biotechnology), or Ifngr1 KO plasmids. Control double nickase plasmid (sc-437281, Santa Cruz Biotechnology) was used as negative control. Two days later, the transduced cells were cultured in EMEM, RPMI 1640, and DMEM complete medium with different concentrations of puromycin for 3 days. Living cells were seeded into 96-well plates with unlimited dilution to reach one cell per well. Knockout clones were validated with Western blot. Plasmids expressing shRNA targeting AP3D1 were packed into a lentivirus packaging construct. LS174T and DLD1 cells were infected with AP3D1 shRNA expressing lentiviruses and selected with 2 and 4 μg/mL puromycin to construct AP3D1 knockdown and control cells in optineurin KO cells. We transducted murine Ifngr1 (Myc-DDK tagged) (vector MR226594, OriGene) and pCMV6-Entry Tagged Cloning Vector (PS100001, OriGene) to construct Ifngr1 overexpressing and control cells in optineurin KO cells. Multiple clones were used for the study.

**Animals**

Six- to 8-week-old male NSG mice and female C57BL/6, BALB/c, Rag1null (Rag−/−), and OT−/I C57BL/6-Tg (TcraTcrb) 1100Mb/j mice (The Jackson Laboratory) were used for this study. All mice were maintained under pathogen-free conditions. Optineurin knockdown, KO, and scramble MC38 cells (3 × 10⁶) or CT26 cells (1 × 10⁶) were subcutaneously injected on the right flank of these mice. Tumor growth was monitored two or three times per week using calipers fitted with a Vernier scale. Tumor volume was calculated as previously described (43). Anti–PD-L1 (clone 53–5.8, Bio X Cell) and IgG1 isotype mAbs were given intraperitoneally at a dose of 100 μg per mouse on day 6 after tumor cell inoculation, then every 3 days for the duration of the experiment. Cerulein was given intraperitoneally at a dose of 30 mg/kg per mouse on day 7 after tumor cell inoculation, then every 3 days for the duration of the experiment.

**Cell Proliferation Assay**

Tumor cells were collected and seeded into 96-well plates. To determine the effect of optineurin deficiency on cell growth, 10% volume of alamar Blue (BDF012, Bio-Rad) was added to the medium and incubated for 4 to 6 hours. Absorbance at wavelengths of 570 nm and 600 nm was measured. The percentage difference in reduction between optineurin−/− and wild-type (optineurinKO) cells was calculated using the following equation: percentage difference between optineurin−/− and wild-type (%) = [(A600 of treatment) − (80,586 × A600 of treatment)]/[A600 of control)] × 100 (43).

**OT-I Cell Isolation and Coculture with Tumor Cells**

Splenocytes were isolated from OT-I C57BL/6-Tg (TcraTcrb) 1100Mb/j. The cells were pelleted, washed, and suspended at 2 × 10⁶ cells/mL in RPMI culture medium containing 5 μg/mL OVA257-264 peptides, 10 ng/mL mouse recombinant IL2, and 50 μg/mL 2-mercaptoethanol. To set up the coculture of OT-I and OVA+ tumor cells, splenic OT-I cells were magnetically purified by EasySep Mouse CD8+ T Cell Isolation Kit (19853, STEMCELL). OT-I cells were activated and collected for coculture. Optineurin−/− and optineurinKO tumor cells were pretreated with OVA peptides (5 μg/mL) for 2 hours. After being washed with phosphate-buffered saline (PBS), OT-I cells were cocultured with these tumor cells at a 1:1 ratio for 24 hours. All cells were collected by trypsinization and analyzed by flow cytometry.

**Quantitative PCR Analysis**

Total RNA was extracted using trizol and phenol–chloroform phase separation. cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR was performed on cDNA using Fast SYBR Green Master Mix (Thermo Fisher Scientific) on a StepOnePlus Real-Time PCR System (Thermo Fisher Scientific). Results are represented as fold change from untreated controls. Primers were purchased from OriGene Technologies. Specific primers are included in Supplementary Table S7.

**Luciferase Assay**

Cells were transfected with a Stat1 homodimer reporter vector (GAS-Luc), negative control, or positive control constructs from the Cignal GAS Reporter Assay Kit (LUC; CCS-009L, QIAGEN). Twenty-four hours after transfection, luciferase activities were measured using the Dual-Luciferase Reporter Assay System (TM040, Promega). Promoter activity was normalized to Renilla luciferase activity and expressed as fold change from control.
Optineurin Controls Colorectal Cancer Immunity

Immunofluorescence Staining and Duo-Link Assay
Optineurin<sup>−/−</sup> and optineurin<sup>+/−</sup> DLD1 cells were treated with different experimental conditions, fixed in 4% paraformaldehyde for 15 minutes, and rinsed with PBS three times. Then, these tumor cells were incubated in blocking buffer (3% BSA and 0.01% saponin in PBS) for 30 minutes at room temperature. The IFNGR1 antibody (GIR-94, sc-12755, Santa Cruz Biotechnology), LAMP1 antibody (D2-D11, 9091, Cell Signaling Technology), or AP3D1 antibody (16454-1-AP, ProteinTech) were diluted in blocking buffer and incubated overnight at 4°C. The secondary antibodies were diluted in blocking buffer and added to the cells for 1 hour at 37°C. Each step was followed by PBS washing three times. Then, 4',6-diamidino-2-phenylindole was used to present the nucleus. The cells were finally mounted with anti-fade mounting medium and detected using a confocal laser scanning microscope. The negative control samples were treated with mouse or rabbit IgG antibodies. Duo-link assay (DUO92101, Sigma-Aldrich) was used to demonstrate the interaction between IFNGR1 and AP3D1. Primary antibodies were IFNGR1 (sc-12755, Santa Cruz Biotechnology) and AP3D1 (16454-1-AP, ProteinTech).

Immunoblotting
Cell lysates were prepared in RIPA Lysis and Extraction Buffer (89901, Thermo Fisher Scientific). The protein concentrations of cell lysates were determined using the Pierce BCA Protein Assay Kit (23225, Thermo Fisher Scientific). Equivalent amounts of total cellular protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (MilliporeSigma). Membranes were blocked with 3% w/v non-fat dry milk and incubated with primary antibodies overnight at 4°C, then conjugated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 2 hours at room temperature. Signal was detected using Clarity and Clarity Max Western ECL Blotting Substrates (Bio-Rad) and captured using the ChemiDoc Imaging System (Bio-Rad). The proteins were detected with specific antibodies. Quantification of intensity was determined by GelPro.

The following antibodies were used for immunoblotting: anti-optineurin (C-2; sc-166576, Santa Cruz Biotechnology), anti-IFNGR1 (GIR-94, sc-12755, Santa Cruz Biotechnology), anti-iL6R (23457-1-AP, ProteinTech), anti-TNFFR1 (3736T, Cell Signaling Technology), anti-PD-L1 (13684, Cell Signaling Technology), anti-AP3D1 (for IP, sc-136277, Santa Cruz Biotechnology; for immunoblots, 16454-1-AP, ProteinTech), anti-phospho-STAT1 (9167, Cell Signaling Technology), anti-STAT1 (14994, Cell Signaling Technology), anti-phospho-STAT3 (9145, Cell Signaling Technology), anti-STAT3 (92405, Cell Signaling Technology), anti-β-actin (D6A8) antibody (8457, Cell Signaling Technology), anti-DYKDDDDK Tag (9A3; 8146, Cell Signaling Technology), and anti-turboGFP (TA150041, OriGene).

Immunoprecipitation and Mass Spectrometry
Co-immunoprecipitation was performed to verify protein interaction. In brief, cell lysates were incubated with indicated antibodies and Protein A/G Plus-Agarose (Santa Cruz Biotechnology) at 4°C overnight. The immune complex was washed three times, then boiled in 2× SDS sample buffer for 10 minutes. The co-precipitates were resolved using SDS-PAGE and blotted with specific antibodies.

IP-MS was used for interactive protein identification. DLD1 cell lysates were incubated with IFNGR1 or optineurin antibodies and Protein A/G Plus-Agarose (Santa Cruz Biotechnology) at 4°C overnight. The immunoprecipitates were resolved using SDS-PAGE and extracted from the gel and subjected to liquid chromatography with tandem mass spectrometry (LC/MS-MS) sequencing by QBiolo Biotechnology Co., Ltd. In brief, proteins were digested in gel and extracted. The extracted fraction was lyophilized and reconstituted with 20 μL of 2% methanol and 0.1% formic acid for sample loading. The samples were separated with the EASY-nLC 1000 system, which was directly interfaced with the Thermo Orbitrap Fusion mass spectrometer. The mass of peptides was identified by the LC/MS-MS Q Exactive Hybrid Quadruple-Orbitrap Mass Spectrometer (Thermo Fisher Scientific). The resulting MS-MS data were searched against the human fasta from UniProt using an in-house Proteome Discoverer (Version PD1.4, Thermo Fisher Scientific). Peptides only assigned to a given protein group were considered unique.

Click-iT Identification of Palmitoylation
We added 100 μmol/L Click-iT palmitic acid–azide to colon cancer cells or the mouse IECs. Cells were incubated at 37°C for 6 hours, then the medium was removed. The cells were washed with PBS before the addition of lysis buffer (1% sodium dodecyl sulfate in 50 mmol/L Tris-HCl, pH 8.0) containing protease and phosphatase inhibitors. The cell lysates were incubated for 30 minutes on ice, sonicated with a probe sonicator, vortexed for 1 minute, and centrifuged at 18,000g at 4°C for 5 minutes. Then, we transferred the supernatants to a tube and determined the protein concentration using the BCA Protein Assay Kit (Thermo Fisher Scientific). The protein samples were reacted with biotin alkyne (764213, Sigma-Aldrich) using the Click-iT Protein Reaction Buffer Kit (C10276, Thermo Fisher Scientific). The biotin alkyne–azide–palmitic acid–protein complexes were pulled down by streptavidin (20347, Thermo Fisher Scientific). The pellets were subjected to immunoblotting for IFNGR1 detection.

IEC and LPMC Isolation
IECs were isolated from optineurin<sup>−/−</sup> (optineurin<sup>+/−</sup>) and optineurin<sup>+/+</sup> (optineurin<sup>−/−</sup>) mice. Fresh intestinal tissue samples were incubated in 10 mL of PBS with 2 mmol/L EDTA, 0.3% BSA, and 0.2% t-glucose for 15 minutes at 37°C under slow rotation (200 rpm) in a thermal incubator. Then, tissues were cut and incubated in 10 mL of PBS with 0.02 g collagenase and 10 μL D-Nase I (10 mg/mL) for 15 minutes at 37°C under slow rotation (200 rpm) in a thermal incubator. Samples were passed through a 100-μm cell strainer and separated by Ficoll density gradient centrifugation. LPMCs were isolated from the inter-media cells after centrifugation.

FACS
For cell surface MHC-I detection, cells were treated and stained with H-2K<sup>β</sup> antibody (553570, BD Biosciences) or H-2D<sup>β</sup> antibody (553580, BD Biosciences) and directly run on a Fortessa flow cytometer (BD Biosciences). For cell surface IFNGR1 detection, cells were treated and stained with IFNGR1 (12-1191-82, Thermo Fisher Scientific). Single cell suspensions were prepared from fresh mouse tumor tissues and LPMCs. Cells were stained with fluorescence conjugated anti-CD45 (560501, BD Biosciences), anti-CD3 (35-0031-82, Thermo Fisher Scientific), anti-CD90 (553004, BD Biosciences), anti-CD4 (17-0042-82, Thermo Fisher Scientific), anti-CD8 (46-0081-82, Thermo Fisher Scientific), anti-EPCAM (17-0579-82, Thermo Fisher Scientific), and anti-CD9 (557644, BD Biosciences), anti-IFN-γ (563854, BD Biosciences), anti-IL12 (554429, BD Biosciences), and anti-FOXP3 (564034, BD Biosciences) mAbs. Cytokine expression was determined by intracellular staining. Anti-granzyme B (560501, BD Biosciences), anti-TNFα (557644, BD Biosciences), anti-IFN-γ (563854, BD Biosciences), and anti-TIM3 (747624, BD Biosciences) mAbs were added to immune cells. For intracellular cytokine staining, we first performed forward scatter (FSC) gating, then side scatter (SSC) gating for single cells under the FSC population. We gated CD90<sup>−</sup> CD3<sup>+</sup> T cells using the SSC population. Then, CD8<sup>+</sup> T cells and CD4<sup>+</sup> T cells were determined in CD90<sup>−</sup> CD3<sup>+</sup> T cells. Granzyme B<sup>+</sup>, TNFα<sup>+</sup>, and IFNγ<sup>+</sup> cells were determined in CD8<sup>+</sup> T-cell and CD4<sup>+</sup> T-cell populations. IL2<sup>+</sup> and FOXP3<sup>+</sup> cells were determined in the CD4<sup>+</sup> T-cell population. Mouse splenocytes were prepared and stained.
with anti-CD8 (564983, BD Biosciences), anti-granzyme B (561142, BD Biosciences), anti-TNF (557644, BD Biosciences), and anti-IFNγ (563773, BD Biosciences). Mouse bone marrow–derived macrophages were prepared and stained with anti-H-2Kb (553570, BD Biosciences). For human optineurin detection, we prepared by staining with anti-optineurin (sc-166576 AF488, Santa Cruz Biotechnology), anti-CD11c (559877, BD Biosciences), anti-CD8 (555368, BD Biosciences), anti-CD4 (562424, BD Biosciences), anti-CD19 (25-0198-42, Thermo Fisher Scientific), anti-CD7 (564020, BD Biosciences), anti-CD33 (561160, BD Biosciences), and anti-CD11c (559877, BD Biosciences). All samples were read on a Fortessa flow cytometer and data were analyzed with DIVA software (BD Biosciences).

**Colorectal Cancer Specimens**

We used paraffin-embedded human colorectal tissue microarrays from three cohorts in this study. Cohorts 1 and 2 were from Shanghai Outdo Biotech. The average follow-up period was 100 months. Cohort 3 was from the Second Department of General Surgery at the Medical University of Lüboin between 2001 and 2013. The average follow-up period was 120 months. Clinical and pathologic information is listed in Supplementary Tables S2 to S5. The four paired colorectal cancer tissues and adjacent normal colorectal tissues were acquired from the Cooperative Human Tissue Network.

**Immunohistochemistry**

The tissue section slides were baked for 60 minutes at 60°C, deparaffinized in xylene, and rehydrated through graded concentrations of ethanol in water. The slides were then subjected to antigen retrieval in 1 × AR6 buffer (PerkinElmer). Immunohistochemistry staining was performed on a Dako Autostainer (Dakko) using Dako LSAB+ and diamobenzidine (DAB) as the chromogen. Tissue sections were labeled with optineurin antibody (C-2; sc-166576, Santa Cruz) or IFNGR1 antibody (10808-1-AP, ProteinTech). Sections were left to air-dry, followed by mounting with permanent mounting medium. Expression of optineurin and IFNGR1 was scored using the H-score method (50, 51). The H-score method took the percentage of positive cells (0%–100%) and each staining intensity (0–3+) into account. A final score was calculated on a continuous scale between 0 and 300 using the following formula: H-score = 1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+). Based on the median value of optineurin and IFNGR1 expression, patients were divided into high and low expression groups. Mouse tumor tissues were fixed in 10% formalin and embedded in paraffin. Immunohistochemistry staining was performed using IFNGR1 antibody (10808-1-AP, ProteinTech).

**Bioinformatics Analysis**

MHC-I and IFN signaling signatures were obtained from the TCGA dataset (http://www.cbioportal.org/). The top 500 genes (log FC > 0, P value from small to large) in IFNγ and MHC-I signaling gene signatures are listed in Supplementary Table S8. Using the Human Protein Atlas (https://www.proteinatlas.org/), protein expression levels of the overlapping 322 genes between the IFNγ and MHC-I signaling gene signatures were analyzed in human normal colorectal tissues based on protein expression score. Based on a single cell sequencing dataset (23), optineurin transcripts were analyzed in different cell subsets in the colorectal cancer microenvironment. Protein expression score was defined as high and low expression based on available protein characterization data (21). Specific proteins were detected by proteomic analysis in human colorectal cancer tissues and normal colorectal tissues (21, 22) and in melanoma tissues in patients having received anti–PD-1 therapy (24). Gene sets represented in the heat-map and gene set enrichment analyses were downloaded from the KEGG pathway database and RECTOME database.

**Statistical Analysis**

Statistical analysis was performed using R and GraphPad Prism8 software. Data were shown as mean ± SEM or mean ± SD. Comparisons of measurement data between two groups were performed using two-tailed t-tests. Comparison of continuous outcomes across multiple experimental groups was performed using analysis of variance (ANOVA) models. Pearson correlation was used to evaluate associations between the expressions of two genes. Survival functions were estimated by Kaplan–Meier methods. Log-rank test was used to calculate statistical differences. P < 0.05 was considered statistically significant.

**Authors’ Disclosures**

W. Zou reports personal fees from CStone, Oncopia, and Hengenix outside the submitted work. No disclosures were reported by the other authors.

**Authors’ Contributions**


**Acknowledgments**

We thank Tomasz Maj for intellectual input and discussion. This work was supported in part by research grants from the U.S. National Cancer Institute, National Institutes of Health (R01CA217648, R01CA123088, R01CA099985, R01CA193136, and R01CA152470 to W. Zou) and by the National Institutes of Health through the University of Michigan Rogel Cancer Center Grant (CA46592).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 28, 2020; revised January 23, 2021; accepted February 19, 2021; published first February 24, 2021.

**REFERENCES**